This is a working overview of collagen peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-01. Anything still debated is marked as such rather than presented as settled.
Collagen peptides are short chains of amino acids derived from collagen, a structural protein found in connective tissues such as skin, bone, and cartilage. The production process involves breaking native collagen into smaller fragments through hydrolysis, which cleaves peptide bonds. Unlike intact collagen, these peptides dissolve in water and do not form a triple helix. Commercial preparations typically contain peptides with molecular weights ranging from about 2,000 to 20,000 daltons. The term collagen peptide is often used interchangeably with hydrolyzed collagen or collagen hydrolysate.
Common sources for collagen peptide production include bovine hide, porcine skin, fish skin, and poultry cartilage. The raw material is first cleaned and then treated with enzymes such as pepsin or microbial proteases under controlled conditions. Hydrolysis time, temperature, and enzyme concentration influence the final peptide size distribution. After hydrolysis, the mixture undergoes filtration, purification, and drying to yield a powder. The amino acid composition is notable for high levels of glycine, proline, and hydroxyproline, which are characteristic of collagen.
The functional properties of collagen peptides depend on their molecular weight profile and amino acid sequence. They are highly soluble in water and produce low-viscosity solutions even at relatively high concentrations. Some peptides exhibit surface activity, which allows them to act as emulsifiers or foaming agents in food systems. The absence of a rigid triple-helical structure distinguishes them from gelatin, which can form gels upon cooling. Chromatographic separation and mass analysis are used to characterize the peptide mixture.
Collagen is a structural protein found in connective tissues of animals, and collagen peptides are short amino acid chains produced by hydrolyzing native collagen into smaller fragments. The hydrolysis process typically uses enzymes or acids under controlled conditions. Commercial collagen peptides often come from bovine hide, porcine skin, or fish scales. The resulting material is water-soluble and differs from intact collagen in molecular size and behavior. The term 'collagen peptide' generally refers to a mixture of peptide chains rather than a single defined molecule.
Production begins with cleaning and mincing raw collagen-rich tissues. The material undergoes pretreatment to remove non-collagenous components, followed by hydrolysis using enzymes such as pepsin or alcalase, or by acid or alkaline treatment. Reaction time, temperature, and pH influence the average molecular weight of the resulting peptides. After hydrolysis, the mixture is filtered, concentrated, and dried, often by spray drying. The final product is a powder with a characteristic amino acid profile rich in glycine, proline, and hydroxyproline.
Collagen peptides are distinguished from gelatin by their lower average molecular weight and better solubility in cold water. Gelatin forms gels upon cooling, while collagen peptides typically do not. Molecular weight distributions for commercial collagen peptides often range from about 2 to 20 kilodaltons, though exact profiles vary by manufacturer and process. Products may be sold as powders, capsules, or liquids. The term "collagen hydrolysate" is frequently used as a synonym, although labeling conventions differ across regions.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for spray-dried commercial preparations |
| Solubility | Water-soluble | Dissolves in cold water; no gel formation |
| Average molecular weight | 2,000–20,000 Da | Varies by hydrolysis time and enzyme |
| Typical storage | Cool, dry, sealed container | Protect from moisture and heat |
| Common synonyms | Hydrolyzed collagen, collagen hydrolysate | Used interchangeably in literature |
Collagen peptides are short chains of amino acids derived from collagen, the main structural protein in connective tissues. They are produced by hydrolysis, which breaks the triple-helical structure of native collagen into smaller fragments. The resulting peptides typically have molecular weights between 2,000 and 10,000 daltons, though commercial preparations vary. Unlike intact collagen, these peptides are water-soluble and do not form gels at room temperature. The term "collagen peptide" often refers to a mixture of fragments rather than a single defined molecule.
Amino acid composition of collagen peptides reflects that of the parent collagen, with glycine, proline, and hydroxyproline being particularly abundant. Glycine appears at nearly every third residue in the repeating sequence Gly-X-Y, where X and Y are often proline or hydroxyproline. This pattern is partly retained in short peptides, though hydrolysis can cleave at various sites. Hydroxyproline is uncommon in most other proteins and serves as a marker for collagen-derived material. The presence of these amino acids contributes to the unique properties of collagen peptides, including their resistance to certain proteases.
Collagen peptides are short chains of amino acids produced by breaking down native collagen, a structural protein found in skin, bone, and connective tissue. The hydrolysis process cleaves the long triple-helical collagen molecule into smaller fragments. These fragments typically range from about 2 to 20 kilodaltons in molecular weight. Unlike intact collagen, collagen peptides dissolve in water and do not form gels. Commercial preparations appear as powders, granules, or liquids.
The amino acid profile of collagen peptides is distinctive. Glycine is the most abundant residue, followed by proline and hydroxyproline. Hydroxyproline is uncommon in other proteins and serves as a useful marker for collagen content. Cysteine and tryptophan are present only in trace amounts. The exact composition depends on the animal source, such as bovine hide, porcine skin, or fish scales, and on the hydrolysis conditions used. Marine sources often contain lower proline and hydroxyproline levels than mammalian sources.
The phase 2 study of LGD-4033 for muscle wasting was finally initiated in November 2016 and was completed with results reported in 2017 and 2018. As of March 2023, LGD-4033 (VK5211) continues to be under development by Viking Therapeutics and continues to be in phase 2 clinical trials for treatment of muscle atrophy and hip fracture.
== FSH and LH preparations == hMG (human Menopausal Gonadotrophins), FSH and LH prepared from human urine collected from postmenopausal women. First extracted in 1953. Injected intra-muscularily (IM) or subcutaneously (SC). Generic
== Potential therapies == A potential novel treatment, the NMT inhibitor, has been shown to completely inhibit Lassa (LAS) and Junín (JUN) viral infections in cells based assays. Another host-directed antiviral acts on EPRS1 which in turn acts, in human cells, as a proviral factor in mammarenaviruses infection, including LCMV, JUNV, and LASV, and its inhibition using halofuginon compound, a prolyl domain inhibitor of EPRS1, completely abolishes the viral infection by interrupting viral assembly and budding. PKR has been shown to act as a proviral factor while the inhibition of its kinase activity restricted the virus replication and infectivity.
Sources: en.wikipedia.org
==== Cancer immunotherapy ==== In 1995, Robert Conry demonstrated that intramuscular injection of naked RNA encoding carcinoembryonic antigen elicited antigen-specific antibody responses. Then, it was elaborated by demonstrating that dendritic cells(DCs) exposed to mRNA coding for specific antigens or to total mRNA extracted from tumor cells and injected into tumor-bearing mice induced T cell immune responses and inhibited the growth of tumors. Then, researchers started to approach mRNA transfected DCs using vaccines based on ex vivo IVT mRNA-transfected DCs. Meanwhile, Argos Therapeutics had initiated a Phase III clinical trial using DCs with advanced renal cell carcinoma in 2015 (NCT01582672) but it was terminated due to the lack of efficacy. For further application, IVT mRNA was optimized for in situ transfections of DCs in vivo. It improved the translation efficiency and stability of IVT mRNA and enhanced the presentation of the mRNA-encoded antigen on MHC class I and II molecules. Then, they found out that the direct injection of naked IVT mRNA into lymph nodes was the most effective way to induce T cell responses. Based on this discovery, first-in-human testing of the injection of naked IVT mRNA encoding cancer antigens by BioNTech has started with patients with melanoma (NCT01684241). Recently, the new cancer immunotherapy, the combining of self-delivering RNA(sd-rxRNA) and adoptive cell transfer(ACT) therapy, was invented by RXi Pharmaceuticals and the Karolinska Institute.
=== Excess and copper antagonism === High levels of molybdenum can interfere with the body's uptake of copper, producing copper deficiency. Molybdenum prevents plasma proteins from binding to copper, and it also increases the amount of copper that is excreted in urine. Ruminants that consume high levels of molybdenum suffer from diarrhea, stunted growth, anemia, and achromotrichia (loss of fur pigment). These symptoms can be alleviated by copper supplements, either dietary and injection. The effective copper deficiency can be aggravated by excess sulfur. Copper reduction or deficiency can also be deliberately induced for therapeutic purposes by the compound ammonium tetrathiomolybdate, in which the bright red anion tetrathiomolybdate is the copper-chelating agent. Tetrathiomolybdate was first used therapeutically in the treatment of copper toxicosis in animals. It was then introduced as a treatment in Wilson's disease, a hereditary copper metabolism disorder in humans; it acts both by competing with copper absorption in the bowel and by increasing excretion. It has also been found to have an inhibitory effect on angiogenesis, potentially by inhibiting the membrane translocation process that is dependent on copper ions. This is a promising avenue for investigation of treatments for cancer, age-related macular degeneration, and other diseases that involve a pathologic proliferation of blood vessels.
==== Phylogenetic motif discovery ==== Motifs have also been discovered by taking a phylogenetic approach and studying similar genes in different species. For example, by aligning the amino acid sequences specified by the GCM (glial cells missing) gene in human, mouse and D. melanogaster, Akiyama and others discovered a pattern which they called the GCM motif in 1996. It spans about 150 amino acid residues, and begins as follows:
Sources: en.wikipedia.org
== Relationship to electroceuticals == In 2012, the global pharmaceutical company GlaxoSmithKline announced an initiative in bioelectric medicine in which the autonomic nervous system's impact on the immune system and inflammatory disease might be treated through electrical stimulation rather than pharmaceutical agents. The company's first investment in 2013 involved a small startup company, SetPoint Medical, which was developing neurostimulators to address inflammatory autoimmune disorders such as rheumatoid arthritis. Ultimately, the electroceuticals quest aims to find the electro-neural signature of disease and, at a cellular level, in real time, play back the more normal electro-signature to help maintain the neural signature in the normal state. Unlike preceding neuromodulation therapy methods, the approach would not involve electrical leads stimulating large nerves or spinal cords or brain centers. It might involve methods that are emerging within the neuromodulation family of therapies, such as optogenetics or some new nanotechnology. Disease states and conditions that have been discussed as targets for future electroceutical therapy include diabetes, infertility, obesity, rheumatoid arthritis, and autoimmune disorders.
==== Stunted growth ==== Untreated OSA in children can also lead to stunted growth. When sleep is disrupted in children who are still growing, there can be significant consequences. Human growth hormone (HGH) is secreted during the night, especially during deep, non-REM sleep. If this is disrupted, growth hormone secretion may be compromised; thus, growth may not occur normally, and children may become shorter than their peers.
A fascial compartment is a section within the body that contains muscles and nerves and is surrounded by fascia. In the human body, the limbs can each be divided into two segments. The upper limb can be divided into the arm and the forearm; their sectional compartments are the fascial compartments of the arm and the fascial compartments of the forearm, which both contain an anterior and a posterior compartment. The lower limbs can also be divided into two segments: the leg and the thigh; those contain the fascial compartments of the leg and the fascial compartments of the thigh respectively.
Sources: en.wikipedia.org
Gelatin is a partially hydrolyzed form of collagen that retains the ability to form gels in water. Collagen peptides undergo more extensive hydrolysis, resulting in shorter chains that dissolve in cold water without gelling. The two products differ in molecular weight distribution and functional behavior.
Bovine hide, porcine skin, fish skin, and poultry cartilage are common sources. The choice of raw material affects the amino acid profile and the resulting peptide sizes. Fish-derived collagen, for example, typically has a lower melting temperature than mammalian collagen.
No. Native collagen is an insoluble structural protein with a triple-helical conformation. Hydrolysis disrupts this structure, producing water-soluble peptides. The biological and functional properties of the peptides differ from those of the intact protein.
They are typically produced from animal connective tissues, such as bovine hide, porcine skin, or fish scales. The raw material is hydrolyzed to break down native collagen into smaller peptide chains.